Resistant hypertension: Diagnosis and management

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 2, 2006, Pages 113-118

  Papadopoulos, Dimitris P ^a   Papademetriou, Vasilios ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Etiology; Resistant hypertension; Therapy

Indexed keywords

ALCOHOL; ANABOLIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; COCAINE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; HYDRALAZINE; LONG ACTING DRUG; MIDODRINE; MINOXIDIL; MONOAMINE OXIDASE INHIBITOR; NICOTINE; PHENOTHIAZINE DERIVATIVE; RESERPINE; SPIRONOLACTONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BLOOD PRESSURE MONITORING; CIGARETTE SMOKING; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVALUATION; FLUID THERAPY; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; LIFE EVENT; OPTIMAL DRUG DOSE; PHEOCHROMOCYTOMA; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RESISTANT HYPERTENSION; STROKE; THYROID DISEASE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD VOLUME; DRUG RESISTANCE; HUMANS; HYPERTENSION; TERMINOLOGY;

EID: 33749033117     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406289735     Document Type: Article

References (51)

1. Vidt DG. Contributing factors in resistant hypertension. Truly refractory disease is rarely found in a properly conducted workup. Postgrad Med. 2000;107:57-60, 63-64, 67-68, 70.
2. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.
3. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Adv Data. 2002;4:1-32.
4. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
5. Cushman WC, Ford CE, Cutler JA, et al; ALLHAT Collaborative Research Group. ALLHAT Collaborative Research Group Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
6. La Batide-Alanore A. Refractory hypertension. Arch Mal Coeur Vaiss. 2000;93(11 suppl):1474-1478.
7. Kaplan N. Resistant hypertension. J Hypertens. 2005;23:1441-1444.
8. Vidt DG. Pathogenesis and treatment of resistant hypertension Minerva Med. 2003Aug;94:201-214.
9. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21:1011-1153.
10. Chobanian AV, Bakris GL, Black HR, et al; Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-2571.
11. Alderman MH, Budner N, Cohen H, Lamport B, Ooi WL. Prevalence of drug resistant hypertension. Hypertension. 1988;11:II71-II75.
12. Swales JD, Bing RF, Heagerty A, Pohl JE, Russell GI, Thurston H. Treatment of refractory hypertension. Lancet. 1982;1:894-896.
13. Taler SJ. Treatment of resistant hypertension. Curr Hypertens Rep. 2005;7:323-329.
14. Werlemann BC, Offers E, Kolloch R. Compliance problems in therapy resistant hypertension. Herz. 2004;29:271-275.
15. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991;151:1786-1792.
16. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR; RUSH University Hypertension Service. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18:619-626.
17. Ram CV. Management of refractory hypertension. Am J Ther. 2003;10:122-126.
18. MacFarlane LL, Orak DJ, Simpson WM. NSAIDs, antihypertensive agents and loss of blood pressure control. Am Fam Physician. 1995;51:849-856.
19. Bravo EL. Phenylpropanolamine and other over-the-counter vasoactive compounds. Hypertension. 1988;11:117-110.
20. Pickering TG. Measurement of blood pressure in and out of the office. J Clin Hypertens (Greenwich). 2005;7:123-129.
21. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension. Blood Press Monit. 2003;8:181-185.
22. Mejia AD, Egan BM, Schork NJ, Zweifler AJ. Artifacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med. 1990;112:270-277.
23. Messerli FH, Ventura HO, Amodeo C. Osler's maneuver and pseudohypertension. N Engl J Med. 1985;312:1548-1551.
24. Andersson O. Management of hypertension. Clinical and hemodynamic studies with special reference to patients refractory to treatment. Acta Med Scand Suppl. 1977;617:1-62.
25. Calhoun DA, Zaman MA, Nishizaka MK. Resistant hypertension. Curr Hypertens Rep. 2002;4:221-228.
26. Stein PP, Black HR.A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Medicine (Baltimore). 1991;70:46-66.
27. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 1992;327:543-547.
28. Van Jaarsveld BC, Krijnen P, Derkx FH, et al. Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens. J Hum Hypertens. 2001;15:669-676.
29. Riccialdelli L, Arnaldi G, Giacchetti G, Pantanetti P, Mantero F. Hypertension due to renal artery occlusion in a patient with antiphospholipid syndrome. Am J Hypertens. 2001;14:62-65.
30. Milanesi F, Barbieri C. A heap of trouble. Resistant hypertension and aneurysm of the renal artery. G Ital Nefrol. 2004;21: 568-570.
31. Andrzejak R, Derkacz A, Poreba R, et al. Renal artery aneurysm as a cause of resistant hypertension in a young female - case report. Kardiol Pol. 2003;59:511-513.
32. Chin BS, Chong AY, Lip GY. A case of resistant hypertension in a 69-year-old man. J Hum Hypertens. 2002;16:445-447.
33. Okeahialam BN. Refractory hypertension in women controlled after identifying and addressing premenstrual syndrome. J Natl Med Assoc. 2004;96:1422-1423.
34. Bloxham CA, Beevers DG, Walker JM. Malignant hypertension and cigarette smoking. Br Med J. 1979;1:581-583.
35. Mukamal KJ, Conigrave KM, Mittleman MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med. 2003;348:109-118.
36. Tuomilehto J, Enlund H, Salonen JT, Nissinen A. Alcohol, patient compliance and blood pressure control in hypertensive patients. Scand J Soc Med. 1984;12:177-181.
37. Dustan HP, Tarazi RC, Bravo EL. Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med. 1972;286:861-866.
38. Isaksson H, Cederholm T, Jansson E, Nygren A, Ostergren J. Therapy-resistant hypertension associated with central obesity, insulin resistance, and large muscle fibre area. Blood Press. 1993;2:46-52.
39. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43:518-524.
40. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342:1378-1384.
41. Lavie P, Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant. Sleep. 2001;24:721-725.
42. Logan AG, Tkacova R, Perlikowski SM, et al. Refractory hypertension and sleep apnea: effect of CPAP on blood pressure and baroreflex. Eur Respir J. 2003;21:241-247.
43. Eggebrecht H, Schmermund A, von Birgelen C, et al. Resistant hypertension in patients with chronic aortic dissection. J Hum Hypertens. 2005;19:227-231.
44. Graves JW. Management of difficult-to-control hypertension. Mayo Clin Proc. 2000;75:278-284.
45. Burnier M, Santschi V, Favrat B, Brunner HR. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens Suppl. 2003;21:S37-S42.
46. Alper AB Jr, Calhoun DA. Contemporary management of refractory hypertension. Curr Hypertens Rep. 1999;1:402-407.
47. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-930.
48. Nishizaka MK,Calhoun DA. The role of aldosterone antagonists in the management of resistant hypertension. Curr Hypertens Rep. 2005;7:343-347.
49. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich). 2004;6: 283-287.
50. Lohmeier TE, Dwyer TM, Hildebrandt DA, et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46:1194-1200.
51. Lohmeier TE, Barrett AM, Irwin ED. Prolonged activation of the baroreflex: a viable approach for the treatment of hypertension? Curr Hypertens Rep. 2005;7:193-198.